High-dose etoposide phosphate (HDEP) is commonly used in combination with total body
irradiation (TBI) prior to allogeneic stem cell transplantation (AlloSCT)[1] and with …

High‐dose etoposide phosphate, a water‐soluble prodrug of etoposide, may be used after
total body irradiation (TBI) in pediatric allogeneic bone marrow transplantation for …

Background Etoposide phosphate (EP; single injection, 60 mg/kg) followed by total body
irradiation (TBI) at 12 Gy has been used as an allogeneic stem cell transplantation (allo …

The pharmacokinetics of two etoposide (E) formulations were evaluated in patients with
refractory hematologic malignancies receiving high-dose conditioning with autologous stem …

Purpose To determine the maximum tolerated dose, toxicities, kinetics, and disposition of
etoposide phosphate when administered as a daily 30‐minute infusion for 5 days. Patients …

Etoposide phosphate, a water soluble prodrug of etoposide, was evaluated at levels
potentially useful in transplantation settings in patients with malignancies. For …

PURPOSE Etoposide has schedule-dependent cytotoxic activity, and clinical resistance may
be overcome with prolonged low-dose therapy. Oral bioavailability is variable, and …

The podophyllotoxin derivatives etoposide and teniposide are active in the treatment of a
variety of malignant conditions. Both represent chemical modifications of podophyllin, an …

Summary Etoposide (VP16–213) is widely used in the treatment of malignant disease and
increasingly high doses are now used in conjunction with autologous bone marrow …

The probability of relapse after allogeneic bone marrow transplantation is as high as 30% in
standard risk patients. Investigators have attempted to improve these results by combining …